News | Hepatitis Central - Part 84

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search

Research & Treatment News

15 Tips for Managing Interferon-Ribavirin Side Effects

May 13, 2008 5 Comments

Many people abandon this challenging HCV treatment mid-course. Here are 15 ways to help manage the side effects of Hepatitis C combination therapy, to help patients' likelihood of completing the extremely challenging treatment. Share this article among patients contemplating and/or already undergoing chemotherapy for Hepatitis C, so they can help increase their likelihood of conquering the virus.

Continue reading »

New Mexico Offers Free Hepatitis C Hotline

May 12, 2008

Finally being recognized as the widespread, public health problem that it is, the New Mexico Department of Health has taken a giant step forward to help people with Hepatitis C. By launching a new, toll-free phone number, locals concerned about Hepatitis C can get some confidential, practical, expert advice.

Continue reading »

Highly Effective Against HCV Genotype 1

May 1, 2008

When tested on people with Hepatitis C genotype 1, R7128 proved to be an effective addition to combination therapy after just four weeks' time. In addition to its anti-viral effect, polymerase inhibitor R7128 received good marks for safety and minimal side effects.

Continue reading »

Investigational Drug Beats Standard Therapy in Hepatitis C Study

Apr 30, 2008

A Phase IIa trial investigating triple combination therapy with PEGASYS, COPEGUS and Roche's investigational drug R1626, demonstrated a higher response rate than traditional combination therapy alone. While R1626's effectiveness and high barrier to resistance makes it a top Hepatitis C contender, the following six months will determine if its ability to clear the virus lasts.

Continue reading »

Improves Outcome for Hep C Genotype 4

Apr 29, 2008

Currently approved for treating contagious diarrhea in children, nitazoxanide has been found to make pegylated interferon-based treatment for Hepatitis C genotype 4 more effective. Prompting new trials in the U.S. and Europe, this drug is now being evaluated for Hepatitis C genotype 1.

Continue reading »

Lapatinib Stabilizes Hepatocellular Carcinoma

Apr 28, 2008

New research was presented at the American Association for Cancer Research supporting the use of Lapatinib for those with advanced liver cancer. Although currently approved for treating breast cancer, this drug represents hope for those who have progressed from chronic Hepatitis C to hepatocellular carcinoma.

Continue reading »

Development of HCV Drug Candidate Ends

Apr 18, 2008

Due to phase II safety trial results, Wyeth Pharmaceuticals and ViroPharma Inc. agreed to discontinue developing their Hepatitis C drug HCV-796. Executives report that HCV-796's capacity to inflict liver damage was too great to maintain its candidacy.

Continue reading »
Article Info
Download our Free Reports Download our Free Reports
Thank You!

You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.

If you still haven't received our email after a few minutes, please feel free to contact us.

Close Window